In addition, it has been reported that KRAS mutations can be found in approximately 92% of pancreatic cancers, and patients with KRAS mutations showed a bad response to first-line gemcitabine-based therapy and presented a poor prognosis [36,37]. This evidence concerns the gene KRAS and pancreatic neoplasm.